Abstract Background and Aims With the liberalization of COVID-19 control policies in mainland China, majority Chinese population has experienced Omicron infection since mid-December 2022. Paxlovid is a commonly used antiviral drug for patients with COVID-19, but there are few studies chronic kidney disease (CKD).Therefore, we conducted retrospective cohort study to explore efficacy CKD at diffe...